Theriva Biologics, Inc.TOVXNYSE
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank56
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P56
Within normal range
vs 2Y Ago
0.3x
Contraction
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 8.34% |
| Q2 2025 | 0.93% |
| Q1 2025 | -1.39% |
| Q4 2024 | -19.88% |
| Q3 2024 | -13.35% |
| Q2 2024 | 29.28% |
| Q1 2024 | 25.38% |
| Q4 2023 | -121.50% |
| Q3 2023 | 24.13% |
| Q2 2023 | 30.62% |
| Q1 2023 | -4.51% |
| Q4 2022 | -20.47% |
| Q3 2022 | -2.30% |
| Q2 2022 | 11.14% |
| Q1 2022 | -1.91% |
| Q4 2021 | -123.10% |
| Q3 2021 | 16.95% |
| Q2 2021 | 22.00% |
| Q1 2021 | -6.26% |
| Q4 2020 | -52.78% |
| Q3 2020 | -1.18% |
| Q2 2020 | 59.15% |
| Q1 2020 | -37.59% |
| Q4 2019 | -17.73% |
| Q3 2019 | -2.68% |
| Q2 2019 | 29.40% |
| Q1 2019 | -28.39% |
| Q4 2018 | 8.66% |
| Q3 2018 | 16.39% |
| Q2 2018 | 29.13% |
| Q1 2018 | -54.60% |
| Q4 2017 | 13.09% |
| Q3 2017 | 21.18% |
| Q2 2017 | 4.46% |
| Q1 2017 | 42.14% |
| Q4 2016 | -73.56% |
| Q3 2016 | -2.10% |
| Q2 2016 | -3.28% |
| Q1 2016 | 48.28% |
| Q4 2015 | 27.89% |